Alaunos Therapeutics (TCRT)
(Delayed Data from NSDQ)
$1.32 USD
+0.16 (13.79%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.33 +0.01 (0.76%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Alaunos Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 3 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 3 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 34 | 38 | 78 | 80 | 58 |
Income After Depreciation & Amortization | -34 | -35 | -78 | -80 | -58 |
Non-Operating Income | 1 | 1 | -1 | 0 | -60 |
Interest Expense | 2 | 3 | 0 | 0 | 0 |
Pretax Income | -35 | -38 | -79 | -80 | -118 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -35 | -38 | -79 | -80 | -118 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -35 | -38 | -79 | -80 | -118 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -31 | -31 | -75 | -79 | -57 |
Depreciation & Amortization (Cash Flow) | 4 | 4 | 3 | 1 | 1 |
Income After Depreciation & Amortization | -34 | -35 | -78 | -80 | -58 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 16.00 | 14.48 | 14.30 | 13.98 | 11.20 |
Diluted EPS Before Non-Recurring Items | -1.90 | -2.55 | -5.55 | -5.70 | -5.10 |
Diluted Net EPS (GAAP) | -2.20 | -2.55 | -5.55 | -5.70 | -10.49 |
Fiscal Year end for Alaunos Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 7.95 | 8.67 | 7.99 | 9.67 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -7.95 | -8.67 | -7.99 | -9.67 |
Non-Operating Income | NA | 0.11 | 0.19 | 0.28 | 0.48 |
Interest Expense | NA | 0.00 | 0.00 | 1.07 | 0.85 |
Pretax Income | NA | -7.84 | -8.48 | -8.77 | -10.05 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -7.84 | -8.48 | -8.77 | -10.05 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -7.84 | -8.48 | -8.77 | -10.05 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 16.01 | 16.00 | 15.99 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.60 | -0.60 | -0.60 |
Diluted Net EPS (GAAP) | NA | -0.40 | -0.60 | -0.60 | -0.60 |